Business, energy, technology, markets and global industry news from Business News Today

Yale Cancer Center

PharmaDeviceNews Yale Cancer Center
Johnson & Johnson targets second-line head and neck cancer treatment with amivantamab
Pharma & Biotech

Rybrevant Faspro shrank tumours in 42% of patients, but can Johnson & Johnson prove survival benefit?

FDA approves Rybrevant Faspro for selected advanced head and neck cancers after a 42% response rate. Survival evidence remains the next test.

Read More
A clinician discusses gastroesophageal cancer diagnosis, biomarker testing, treatment options and clinical trials with patients and caregivers ahead of the Debbie’s Dream Foundation and Yale Cancer Center community symposium. Representative image.
Pharma & Biotech

Debbie’s Dream Foundation expands patient education through Yale Cancer Center collaboration

Yale and Debbie’s Dream Foundation will explain diagnosis, biomarkers, treatment, trials and supportive care at a free cancer symposium.

Read More